Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer
Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA ESTUDIO CON MÚLTIPLES DOSIS PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD, LA FARMACOCINÉTICA, LA FARMACODINÁMICA Y LA EFICACIA DE LA ADMINISTRACIÓN DE PF-06741086 POR VÍA SUBCUTÁNEA O INTRAVENOSA EN SUJETOS CON HEMOFILIA GRAVE
To determine the safety and tolerability of multiple doses of PF-06741086 administered to severe hemophilia A and B subjects. Determinar la seguridad y la tolerabilidad de múltiples dosis de PF ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 5 ans
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
To compare the proportion of patients demonstrating Major Molecular Response (MMR) at 12 months (48 weeks) in the bosutinib arm with that of the imatinib arm in newly diagnosed Philadelphia chromosome...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Limited
Update Il y a 5 ans
A CLUSTER RANDOMIZED TRIAL ON CARDIOVASCULAR RISK FACTOR MANAGEMENT: CADUET® VERSUS USUAL CARE IN SUBJECTS WITH HYPERTENSION AND ADDITIONAL CARDIOVASCULAR RISK FACTORS IN CLINICAL PRACTICE
To investigate whether a Caduet®-based multi-factorial risk factor management strategy might result in greater reduction in total cardiovascular risk as compared with a usual care strategy after one y...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
1. To compare the efficacy of CP 690,550, as monotherapy, in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA), in subjects with RA wh...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Ltd
Update Il y a 5 ans
A PHASE IIb RANDOMISED DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-00610355 OVER 4 WEEKS IN MODERATE ASTHMATIC SUBJECTS
To assess the efficacy of PF-00610355 (‘once daily’ QD doses of 100 mcg, 300 mcg and 600 mcg) in the treatment of moderate asthma following 4 weeks treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
Update Il y a 5 ans
Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma
Phase I To determine the maximum tolerated dose (MTD) and RP2D of PD 0332991 in combination with bortezomib and dexamethasone Phase II To evaluate the anti-tumor activity of PD 0332991 in com...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Ltd
Update Il y a 5 ans
An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a single-dose 2.0g azithromycin microspheres regimen in subjects with acute bacterial sinusitis
Main objective :To characterize the pharmacokinetics of azithromycin in maxillary sinus aspirate and in serum in adult subjects with acute bacterial sinusitis after treatment with azithromycin IR 500 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetes
To evaluate the efficacy of PF-00489791 in the reduction of albuminuria in subjects with type 2 diabetes and overt nephropathy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company
Update Il y a 5 ans
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma
To evaluate efficacy as measured by progression-free survival (PFS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared wit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
Update Il y a 5 ans
A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis
To demonstrate the efficacy of CP 690,550 in inducing remission in subjects with moderately to severely active ulcerative colitis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
18
19
20
21
22
23
24
25
26
27
Next